In this piece, we will discuss the 8 Most Promising Robotics Stocks Now.
The robotics boom is no longer a distant prediction. Robotics adoption is accelerating across industries, driven by advances in artificial intelligence, automation, and sensing technologies. As companies invest in greater efficiency and autonomy, investors are increasingly looking for stocks that could benefit from these long-term trends.
On June 3, 2026, CNBC reported that SoftBank CEO Masayoshi Son identified physical AI and robotics as the space most likely to produce the next trillion-dollar company. That same week, Zornitza Todorova, head of thematic FICC research at Barclays, told CNBC’s Squawk Box Europe that the humanoid robotics market, currently worth just $2 to $3 billion, is on track to reach $200 billion by 2035, calling this “the decade of the robot.”
The forecasts are already accelerating. On June 24, 2026, CNBC reported that Morgan Stanley had sharply upgraded its China humanoid shipment forecast for the second time this year, now projecting 50,000 units shipped in 2026, nearly double its prior estimate of 28,000 and more than triple its January projection of 14,000. The investment bank estimates China’s humanoid robot market will hit $2 billion this year and scale to $15 billion by 2030.
China remains the dominant force in the robotics market. Barclays’ report noted that China installs roughly half of all industrial robots globally and accounted for 85% of humanoid robot installations last year, producing machines at nearly half the cost of Western competitors. Wedbush Securities’ Dan Ives told CNBC on June 3 that China is “right now the clear leader,” with the U.S. in “catch-up mode.”
Scaling the technology remains a formidable challenge. Reuters Breakingviews reported on June 11 that Unitree Robotics, the world’s largest humanoid maker by sales last year, saw first-quarter adjusted net profit fall 53% year-over-year even as sales rose 68%, with the company attributing the squeeze to rising R&D costs and price cuts as new rivals crowd in.
The IPO pipeline reinforces that point: at least 46 robotics companies are queued for listings in Hong Kong alone, and China has over 450,000 registered companies in the sector, according to state media. With technology still maturing, and even advanced models currently lacking the dexterity for basic tasks outside controlled environments, and competition intensifying across the board, the path from promise to profit remains anything but straightforward.
With that industry overview in mind, here are the most promising robotics stocks now.
Our Methodology
For this article, we screened U.S.-listed robotics stocks from various ETFs, focusing on companies that build robots, supply components for robotic systems, offer robotics-as-a-service solutions, or develop AI and software platforms for autonomous applications. We then evaluated each stock’s upside potential and hedge fund ownership in Q1 2026, ranking the final list by upside potential (street-high). To assess hedge fund sentiment, we relied on Insider Monkey’s hedge fund database, which tracks over 1,000 elite hedge fund managers and their holdings as of Q1 2026.
Note: All data sourced on June 24, 2026.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
8. PROCEPT BioRobotics Corporation (NASDAQ:PRCT)
Number of Hedge Fund Holders: 28
Upside Potential: 147.60%
With significant hedge fund interest and strong upside, PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is one of the most promising robotics stocks.
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is building a clinical case for Aquablation that could redefine its addressable market, with two major prostate cancer study milestones drawing fresh analyst attention to the stock.
On May 28, 2026, PROCEPT BioRobotics Corporation (NASDAQ:PRCT) announced two milestones in its WATER IV prostate cancer clinical program.
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) completed enrollment in the WATER IV RP study, a randomized trial comparing Aquablation therapy to radical prostatectomy in 280 patients, the only FDA randomized study of its kind. Primary endpoint results are expected to be presented at the American Urological Association Annual Meeting in spring 2027.
Alongside that, PROCEPT BioRobotics Corporation (NASDAQ:PRCT) received FDA Investigational Device Exemption (IDE) approval for a second protocol, WATER IV AS, which will enroll up to 333 patients globally to evaluate Aquablation therapy versus active surveillance in men with Grade Group 1 and 2 prostate cancer. Patients in both studies will be followed for ten years, with assessments covering disease control and quality-of-life outcomes, including urinary, sexual, and overall function.
That clinical progress drew a bullish response from Wall Street.
On June 24, 2026, Evercore ISI analyst Vijay Kumar initiated coverage of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) with an “Outperform” rating and a $30 price target. Kumar cited Aquablation as having the best clinical evidence in the space and argued that a positive WATER IV trial outcome over the next 12 months could expand the total addressable market into prostate cancer while supporting multiple expansion for the stock.
Procept BioRobotics Corporation (NASDAQ:PRCT) is a commercial-stage surgical robotics company that develops transformative solutions in urology in the U.S. and internationally.
7. NVIDIA Corporation (NASDAQ:NVDA)
Number of Hedge Fund Holders: 275
Upside Potential: 150.00%
Given its significant hedge fund backing and attractive upside potential, NVIDIA Corporation (NASDAQ:NVDA) is one of the most promising robotics stocks.
NVIDIA Corporation (NASDAQ:NVDA) is extending its physical AI ambitions on two fronts simultaneously, pushing deeper into industrial robotics safety while advancing its push into agentic life sciences.
On June 23, 2026, NVIDIA Corporation (NASDAQ:NVDA) announced the NVIDIA BioNeMo Agent Toolkit, a platform that equips AI agents with domain-specific life sciences tools spanning protein structure prediction, molecular docking, generative chemistry, genomic analysis, and biomarker discovery.
The toolkit draws on more than a decade of NVIDIA life sciences libraries and is powered by NIM microservices, Parabricks, NeMo, and Nemotron technologies. More than 50 companies are already using it, including Anthropic, OpenAI, Lilly, and Natera, with collaborations also spanning scientific data platforms, lab automation companies, and AI-native biology firms.
NVIDIA Corporation (NASDAQ:NVDA) said the toolkit can compress virtual screening timelines from days to minutes and has already delivered 2x faster performance for protein design models like RosettaFold3 through a collaboration with the University of Washington’s Institute for Protein Design.
A day earlier, NVIDIA Corporation (NASDAQ:NVDA) announced NVIDIA Halos for Robotics, described as the industry’s first full-stack safety system for robotics and physical AI, drawing on more than 18,600 years of engineering experience in autonomous vehicle safety development. The system spans AI compute, safety software, sensor data, and an ANAB-accredited inspection lab for functional and AI safety certification.
Agility, whose humanoid robot Digit operates in facilities for Amazon, GXO, Schaeffler, and Motor Manufacturing Canada, is the first company to integrate NVIDIA Halos for Robotics into its safety architecture.
NVIDIA Corporation (NASDAQ:NVDA) is a fabless semiconductor and AI computing company that designs GPUs, AI accelerators, Application Programming Interfaces (APIs), and system-on-a-chip units. Through its CUDA ecosystem, the company enables industries ranging from autonomous vehicles to scientific research by advancing AI, accelerated computing, and data center infrastructure.
6. Stereotaxis, Inc. (NYSEAMERICAN:STXS)
Number of Hedge Fund Holders: 10
Upside Potential: 185.70%
Given its significant hedge fund backing and attractive upside potential, Stereotaxis, Inc. (NYSEAMERICAN:STXS) is one of the most promising robotics stocks.
Stereotaxis, Inc. (NYSEAMERICAN:STXS) is navigating a pivotal product transition, with fresh regulatory wins and a transformational acquisition reshaping its commercial runway, even as near-term results reflect the costs of that transition.
Last month, Stereotaxis, Inc. (NYSEAMERICAN:STXS) reported first-quarter 2026 results, with revenue of $6.3 million, down from $7.5 million in the prior year period. System revenue came in at $1.3 million and recurring revenue at $5.0 million, compared to $2.0 million and $5.5 million, respectively, in Q1 2025. The company said recurring revenue remains pressured by the wind-down of its legacy Johnson & Johnson catheter relationship, with new proprietary catheters still contributing modestly.
Meanwhile, gross margin for the quarter was 60%, with recurring revenue gross margin at 66% and system gross margin at 39%. Operating loss was $6.0 million, and net loss was $5.9 million, while adjusted operating loss, excluding non-cash charges, was $2.9 million. Stereotaxis, Inc. (NYSEAMERICAN:STXS) ended the quarter with $14.6 million in cash and no debt, and noted that demand for its MAGiC cardiac ablation catheter far exceeds current supply, with manufacturing targeted to reach 500 catheters per month by year-end.
Citizens maintained its “Market Outperform” rating on Stereotaxis, Inc. (NYSEAMERICAN:STXS) with a $4.00 price target, with analyst Daniel Stauder pointing to a compelling razor/razor blade ecosystem as a driver of sustainable growth.
The firm views Stereotaxis, Inc. (NYSEAMERICAN:STXS) as a unique microcap worth owning, citing developing tailwinds for system adoption and improved procedural utilization through 2026 and into 2027. Citizens’ $4.00 target is based on an EV/revenue multiple of roughly 6x to 7x applied to its 2027 total sales estimate of $53 million, a premium multiple the firm considers reasonable given an expected approximately 30% top-line growth profile.
Stereotaxis, Inc. (NYSEAMERICAN:STXS) designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory. Its primary products are the Genesis RMN System, the Odyssey Solution, and other related devices.
While we acknowledge the potential of STXS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than STXS and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 most promising robotics stocks now.
Disclosure: None. Follow Insider Monkey on Google News.
